The hypoxic tumor microenvironment: A driving force for breast cancer progression

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1863, Issue 3, 2016, Pages 382-391

  Semenza, Gregg L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone metastasis; Lung metastasis; Lymph node metastasis; Mesenchymal stem cells; Microvesicles; Myeloid derived suppressor cells; Tumor associated macrophages

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; COLLAGEN; COLONY STIMULATING FACTOR 1; CXCL16 CHEMOKINE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR 3ALPHA; LYSINE OXIDASE; MYOSIN; MYOSIN LIGHT CHAIN; OXYGEN; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PROCOLLAGEN LYSINE 2 OXOGLUTARATE 5 DIOXYGENASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN KINASE; PROTEIN LYSINE 6 OXIDASE; RHO ASSOCIATED COILED COIL FORMING KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STEM CELL FACTOR RECEPTOR; STROMAL CELL DERIVED FACTOR 1; TELOPEPTIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; HYPOXIA INDUCIBLE FACTOR 1;

AXILLARY LYMPH NODE; BONE METASTASIS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL; CANCER STEM CELL; CELL SURVIVAL; COLLAGEN FIBER; DISTANT METASTASIS; ENZYME ACTIVATION; HUMAN; HYDROXYLATION; HYPOXIA; IMMUNOSURVEILLANCE; INFLAMMATION; INTRADUCTAL CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MEMBRANE MICROPARTICLE; MESENCHYMAL STEM CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; TUMOR MICROENVIRONMENT; BIOLOGICAL MODEL; BREAST NEOPLASMS; CELL HYPOXIA; CELL MOTION; DISEASE COURSE; FEMALE; METABOLISM; PATHOLOGY;

BREAST NEOPLASMS; CELL HYPOXIA; CELL MOVEMENT; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MODELS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84955192227     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2015.05.036     Document Type: Review

References (105)

1. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
2. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
3. Bissell M.J., Hines W.C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 2011, 17:320-329.
4. The Cancer Genome Atlas Network Comprehensive molecular portrait of human breast tumors. Nature 2012, 490:61-70.
5. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
6. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005, 10(Suppl. 3):20-29.
7. 2 histography. Antioxid. Redox Signal. 2007, 9:1221-1235.
8. Vaupel P., Mayer A., Höckel M. Tumor hypoxia and malignant progression. Methods Enzymol. 2004, 381:335-354.
9. Harris A.L. Hypoxia - a key regulatory factor in tumor growth. Nat. Rev. Cancer 2002, 2:38-47.
10. Prabhakar N.R., Semenza G.L. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol. Rev. 2012, 92:967-1003.
11. Semenza G.L. Hypoxia-inducible factors in physiology and medicine. Cell 2012, 148:399-408.
12. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 2008, 30:393-402.
13. Semenza G.L. Hypoxia-inducible factor 1 and cardiovascular disease. Annu. Rev. Physiol. 2014, 76:39-56.
14. Dales J.P., Garcia S., Meunier-Carpentier S., Andrac-Meyer L., Haddad O., Lavaut M.N., Allasia C., Bonnier P., Charpin C. Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int. J. Cancer 2005, 116:734-739.
15. Schindl M., Schoppmann S.F., Samonigg H., Hausmaninger H., Kwasny W., Gnant M., Jakesj R. Overexpression of hypoxia-inducible factor 1α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 2002, 8:1831-1837.
16. Bos R., van der Groep P., Greijer A.E., Shvarts A., Meijer S., Pinedo H.M., Semenza G.L., van Diest P.J., van der Wall E. Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97:1573-1581.
17. Giatromanolaki A., Koukourakis M.I., Simopoulos C., Polychronidis A., Gatter K.C., Harris A.L., Sivridis E. c-ErbB-2 related aggressiveness in breast cancer is hypoxia-inducible factor-1α dependent. Clin. Cancer Res. 2004, 10:7972-7977.
18. Generali D., Berruti A., Brizzi M.P., Campo L., Bonardi S., Wigfield S., Bersiga A., Allevi G., Milani M., Aguggini S., Gandolfi V., Dogliotti L., Bottini A., Harris A.L., Fox S.B. Hypoxia-inducible factor-1α expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin. Cancer Res. 2006, 12:4562-4568.
19. Yamamoto Y., Ibusuki M., Okumura Y., Kawasoe T., Kai K., Ivama K., Iwase H. Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res. Treat. 2008, 110:465-475.
20. Winter S.C., Buffa F.M., Silva P., Miller C., Valentine H.R., Turley H., Shah K.A., Cox G.J., Corbridge R.J., Homer J.J., Musgrove B., Slevin N., Sloan P., Price P., West C.M., Harris A.L. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 2007, 67:3441-3449.
21. Samanta D., Gilkes D.M., Chaturvedi P., Xiang L., Semenza G.L. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E5429-E5438.
22. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
23. Liao D., Johnson R.S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007, 26:281-290.
24. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology. Oncogene 2010, 29:625-634.
25. Liao D., Corle C., Seagroves T.N., Johnson R.S. Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 2007, 67:563-572.
26. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16:4604-4613.
27. Bos R., Zhong H., Hanrahan C.F., Mommers E.C., Semenza G.L., Pinedo H.M., Abeloff M.D., Simons J.W., van Diest P.J., van der Wall E. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J. Natl. Cancer Inst. 2001, 93:309-314.
28. Lee K., Qian D.Z., Rey S., Wei H., Liu J.O., Semenza G.L. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2353-2358.
29. Ran S., Volk L., Hall K., Flister M.J. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 2010, 17:229-251.
30. Cailleau R., Young R., Olivé M., Reeves W.J. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 1978, 53:661-674.
31. Schito L., Rey S., Tafani M., Zhang H., Wong C.C., Russo A., Russo M.A., Semenza G.L. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E2707-E2716.
32. Hiraga T., Kizaka-Kondoh S., Hirota K., Hiraoka M., Yoneda T. Hypoxia and hypoxia-inducible factor 1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 2007, 67:4157-4163.
33. Dunn L.K., Mohammed K.S., Fournier P.G., McKenna C.R., Davis H.W., Niewolna M., Peng X.H., Chirgwin J.M., Guise T.A. Hypoxia and TGF-β drive breast cancer metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One 2009, 4:e6896.
34. Subarsky P., Hill R.P. The hypoxic tumor microenvironment and metastatic progression. Clin. Exp. Metastasis 2003, 20:237-250.
35. Zhang H., Wong C.C., Wei H., Gilkes D.M., Korangath P., Chaturvedi P., Schito L., Chen J., Krishnamachary B., Winnard P.T., Raman V., Zhen L., Mitzner W.A., Sukumar S., Semenza G.L. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 2012, 31:1757-1770.
36. Wyckoff J., Wang W., Lin E.Y., Wang Y., Pixley F., Stanley E.R., Graf T., Pollard J.W., Segall J., Condeelis J. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004, 64:7022-7029.
37. Goswami S., Sahai E., Wyckoff J.B., Cammer M., Cox D., Pixley F.J., Stanley E.R., Segall J.E., Condeelis J.S. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 2005, 65:5278-5283.
38. Noy R., Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014, 41:49-61.
39. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumor stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
40. Chaturvedi P., Gilkes D.M., Wong C.C., Kshitiz, Luo W., Zhang H., Wei H., Takano N., Schito L., Levchenko A., Semenza G.L. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J. Clin. Invest. 2013, 123:189-205.
41. Chaturvedi P., Gilkes D.M., Takano N., Semenza G.L. Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E2120-E2129.
42. Boudreau A., van't Veer L.J., Bissell M.J. An "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity. Cell Adhes. Migr. 2012, 6:236-2489.
43. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
44. Hasebe T., Tsuda H., Tsubono Y., Imoto S., Mukai K. Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence and tumor death within three years after the initial operation. Jpn. J. Cancer Res. 1997, 88:590-599.
45. Pauling L., Corey R.B. The structure of fibrous proteins of the collagen-gelatin group. Proc. Natl. Acad. Sci. U. S. A. 1951, 37:272-281.
46. Gorres K.L., Raines R.T. Prolyl-4-hydroxylase. Crit. Rev. Biochem. Mol. Biol. 2010, 45:106-204.
47. Hofbauer K.H., Gess B., Lohaus C., Meyer H.E., Katschinski D., Kurtz A. Oxygen tension regulates the expression of a group of procollagen hydroxylases. Eur. J. Biochem. 2003, 270:4515-4522.
48. Yamauchi M., Sricholpech M. Lysine post-translational modifications of collagen. Essays Biochem. 2012, 52:113-133.
49. Butcher D.T., Alliston T., Weaver V.M. A tense situation: forcing tumor progression. Nat. Rev. Cancer 2009, 9:108-122.
50. Gilkes D.M., Semenza G.L., Wirtz D. Hypoxia and the extracellular matrix: drivers of tumor metastasis. Nat. Rev. Cancer 2014, 14:430-439.
51. Erler J.T., Bennewith K.L., Nicolau M., Dornhöfer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
52. Schietke R., Warnecke C., Wacker I., Schödel J., Mole D.R., Campean V., Amann K., Goppelt-Struebe M., Behrens J., Eckardt K.U., Wiesener M.S. The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. J. Biol. Chem. 2010, 285:6658-6669.
53. Wong C.C., Gilkes D.M., Zhang H., Chen J., Wei H., Chaturvedi P., Fraley S.J., Wong C.M., Khoo U.S., Ng I.O., Wirtz D., Semenza G.L. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:16369-16374.
54. Gilkes D.M., Chaturvedi P., Bajpai S., Wong C.C., Wei H., Pitcairn S., Hubbi M.E., Wirtz D., Semenza G.L. Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res. 2013, 73:3285-3296.
55. Gilkes D.M., Bajpai S., Wong C.C., Chaturvedi P., Hubbi M.E., Wirtz D., Semenza G.L. Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Mol. Cancer Res. 2013, 11:456-466.
56. Chambers A.F. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?. Cancer Res. 2009, 69:5292-5293.
57. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., Zhu Z., Hicklin D., Wu Y., Port J.L., Altorki N., Port E.R., Ruggero D., Shmelkov S.V., Jensen K.K., Rafii S., Lyden D. VEGFR1-positive hematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
58. Sceneay J., Smyth M.J., Möller A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 2013, 32:449-464.
59. Erler J.T., Bennewith K.L., Cox T.R., Lang G., Bird D., Koong A., Le Q.T., Giaccia A.J. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15:35-44.
60. Wong C.C., Zhang H., Gilkes D.M., Chen J., Wei H., Chaturvedi P., Hubbi M.E., Semenza G.L. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J. Mol. Med. 2012, 90:803-815.
61. El-Haibi C.P., Bell G.W., Zhang J., Collmann A.Y., Wood D., Scherber C.M., Csizmadia E., Mariani O., Zhu C., Campagne A., Toner M., Bhatia S.N., Irimia D., Vincent-Salomon A., Karnoub A.E. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:17460-17465.
62. Lindsey S., Langhans S.A. Crosstalk of oncogenic signaling pathways during epithelial-mesenchymal transition. Front. Oncol. 2014, 4:358.
63. Narumiya S., Tanji M., Ishizaki T. Rho signaling, ROCK, and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev. 2009, 28:65-76.
64. Olson M.F., Sahai E. The actin cytoskeleton in cancer cell motility. Clin. Exp. Metastasis 2009, 26:273-287.
65. Plotnikov S.V., Waterman C.M. Guiding cell migration by tugging. Curr. Opin. Cell Biol. 2013, 25:619-626.
66. Wang W., Goswami S., Lapidus K., Wells A.L., Wyckoff J.B., Sahai E., Singer R.H., Segall J.E., Condeelis J.S. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res. 2004, 64:8585-8594.
67. Belizzi A., Mangia A., Chiriatti A., Petroni S., Quaranta M., Schittulli F., Malfettone A., Cardone R.A., Paradiso A., Reshkin S.J. RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease. Int. J. Mol. Med. 2008, 22:25-31.
68. Lane J., Martin T.A., Watkins G., Mansel R.E., Jiang W.G. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int. J. Oncol. 2008, 33:585-593.
69. Graham C.H., Fitzpatrick T.E., McCrae K.R. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood 1998, 91:3300-3307.
70. Krishnamachary B., Berg-Dixon S., Kelly B., Agani F., Feldser D., Ferreira G., Iyer N., LaRusch J., Pak B., Taghavi P., Semenza G.L. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 2003, 63:1138-1143.
71. Ginis I., Faller D.V. Hypoxia affects tumor cell invasiveness in vitro: the role of hypoxia-activated ligand HAL1/13 (Ku86 autoantigen). Cancer Lett. 2000, 154:163-174.
72. Funamoto K., Zervantonakis I.K., Liu Y., Ochs C.J., Kim C., Kamm R.D. A novel microfluidic platform for high-resolution imaging of a three-dimensional cell culture under a controlled hypoxic environment. Lab Chip 2012, 12:4855-4863.
73. Gilkes D.M., Xiang L., Lee S.J., Chaturvedi P., Hubbi M.E., Wirtz D., Semenza G.L. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E384-E393.
74. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
75. Regan Anderson T.M., Peacock D.L., Daniel A.R., Hubbard G.K., Lofgren K.A., Girard B.J., Schörg A., Hoogewijs D., Wenger R.H., Seagroves T.N., Lange C.A. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Cancer Res. 2013, 73:5810-5820.
76. Padua D., Zhang X.H., Wang Q., Nadal C., Gerald W.L., Gomis R.R., Massagué J. TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133:66-77.
77. Li Z., Bao S., Wu Q., Wang H., Eyler C., Sathornsumetee S., Shi Q., Cao Y., Lathia J., McLendon R.E., Hjelmeland A.B., Rich J.N. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15:759-772.
78. Conley S.J., Gheordunescu E., Kakarala P., Newman B., Korkaya H., Heath A.N., Clouthier S.G., Wicha M.S. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2784-2789.
79. Schwab L.P., Peacock D.L., Majumdar D., Ingels J.F., Jensen L.C., Smith K.D., Cushing R.C., Seagroves T.N. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res. 2012, 14:R6.
80. Cordenonsi M., Zanconato F., Azzolin L., Forcato M., Rosato A., Frasson C., Inui M., Montagner M., Parenti A.R., Poletti A., Daidone M.G., Dupont S., Basso G., Bicciato S., Piccolo S. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011, 147:759-772.
81. Pan D. The Hippo signaling pathway in development and cancer. Dev. Cell 2010, 19:491-505.
82. Xiang L., Gilkes D.M., Hu H., Takano N., Luo W., Lu H., Bullen J.W., Samanta D., Liang H., Semenza G.L. Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget 2014, 5:12509-12527.
83. Ma B., Chen Y., Chen L., Cheng H., Mu C., Li J., Gao R., Zhou C., Cao L., Liu J., Zhu Y., Chen Q., Wu S. Hypoxia regulates Hippo signaling through the SIAH2 ubiquitin E3 ligase. Nat. Cell Biol. 2005, 17:95-103.
84. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum B., Wicha M.S., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
85. Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., Pilotti S., Pierotti M.A., Daidone M.G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005, 65:5506-5511.
86. Bendinelli P., Maroni P., Matteucci E., Luzatti A., Perrucchini G., Desiderio M.A. Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer. Eur. J. Cancer 2013, 49:2608-2618.
87. D'Souza-Schorey C., Clancy J.W. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev. 2012, 26:1287-1299.
88. Kahlert C., Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J. Mol. Med. 2013, 91:431-437.
89. Roberts C.T., Kurre P. Vesicle trafficking and RNA transfer add complexity and connectivity to cell-cell communication. Cancer Res. 2013, 73:3200-3205.
90. Azmi A.S., Bao B., Sarkar F.H. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013, 32:623-642.
91. Ostrowski M., Carmo N.B., Krumeich S., Fanget I., Raposo G., Savina A., Moita C.F., Schauer K., Hume A.N., Freitas R.P., Gould B., Benaroch P., Hacohen N., Fukuda M., Desnos C., Seabra M.C., Darchen F., Amigorena S., Moita L.F., Thery C. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 2010, 12:19-30.
92. Peinado H., Alečković M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., Hergueta-Redondo M., Williams C., García-Santos G., Ghajar C., Nitadori-Hoshino A., Hoffman C., Badal K., Garcia B.A., Callahan M.K., Yuan J., Martins V.R., Skog J., Kaplan R.N., Brady M.S., Wolchok J.D., Chapman P.B., Kang Y., Bromberg J., Lyden D. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891.
93. Wysoczynski M., Ratajczak M.Z. Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. Int. J. Cancer 2009, 125:1595-1603.
94. Park J.E., Tan H.S., Datta A., Lai R.C., Zhang H., Meng W., Lim S.K., Sze S.K. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol. Cell. Proteomics 2010, 9:1085-1099.
95. Svensson K.J., Kucharzewska P., Christianson H.C., Sköld S., Löfstedt T., Johansson M.C., Mörgelin M., Bengzon J., Ruf W., Belting M. Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:13147-13152.
96. Kucharzewska P., Christianson H.C., Welch J.E., Svensson K.J., Fredlund E., Ringnér M., Mörgelin M., Bourseau-Guilmain F., Bengzon J., Belting M. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:7312-7317.
97. Umezu T., Tadokoro H., Azuma K., Yoshikawa S., Ohyashiki K., Ohyashiki J.H. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor inhibiting HIF-1. Blood 2014, 124:3748-3757.
98. King H.W., Michael M.Z., Gleadle J.M. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 2012, 12:421.
99. Galindo-Hernandez O., Villegas-Comonfort S., Candanedo F., González-Vázquez M.C., Chavez-Ocaña S., Jimenez-Villanueva X., Sierra-Martinez M., Salazar E.P. Elevated concentration of microvesicles isolated from peripheral blood in breast cancer patients. Arch. Med. Res. 2013, 44:208-214.
100. Wang T., Gilkes D.M., Takano N., Xiang L., Luo W., Bishop C.J., Chaturvedi P., Green J.J., Semenza G.L. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E3234-E3242.
101. Aga M., Bentz G.L., Raffa S., Torrisi M.R., Kondo S., Wakisaka N., Yoshizaki T., Pagano J.S., Shackelford J. Exosomal HIF-1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes. Oncogene 2014, 33:4613-4622.
102. Luo W., Chang R., Zhong J., Pandey A., Semenza G.L. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E3367-E3376.
103. O'Toole S.A., Beith J.M., Millar E.K., West R., McLean A., Cazet A., Swarbrick A., Oakes S.R. Therapeutic targets in triple negative breast cancer. J. Clin. Pathol. 2013, 66:530-542.
104. Xiang L., Gilkes D.M., Chaturvedi P., Luo W., Hu H., Takano N., Liang H., Semenza G.L. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. J. Mol. Med. 2014, 92:151-164.
105. Zhao T., Ren H., Jia L., Chen J., Xin W., Yan F., Li J., Wang X., Gao S., Qian D., Huang C., Hao J. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget 2015, 6:2250-2262.